Why AbbVie Stock Dipped in 2019
Shares of pharma giant AbbVie (NYSE: ABBV) dipped by 3.96% over the course of 2019, according to data from S&P Global Market Intelligence. The drugmaker's stock slipped last year for two fundamental reasons:
Prior to 2019, AbbVie's shares had appreciated by a whopping 163% since the company's debut as an independent entity in 2013, making it one of the best-performing large-cap pharma stocks over this period. The company's early success, however, was due in large part to Humira's skyrocketing sales.
Image source: Getty Images.
Source Fool.com
